Drug intelligence / Profile preview

statins + ezetimibe + bempedoic acid + evolocumab + alirocumab + inclisiran

Development stage: Unknown
Lead developer: Universitätsklinikum Jena
Modality: Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Oral, Subcutaneous

Overview

This entry refers to a comprehensive lipid-lowering therapeutic regimen evaluated in the **Germany on Target** clinical trial (NCT05521100) led by **Jena University Hospital**. The regimen includes a combination of standard-of-care and advanced lipid-lowering agents: HMG-CoA reductase inhibitors (**statins**), the cholesterol absorption inhibitor **ezetimibe**, the ATP citrate lyase inhibitor **bempedoic acid**, and PCSK9 inhibitors (the monoclonal antibodies **evolocumab** and **alirocumab**, and the siRNA **inclisiran**). The protocol utilizes a cloud-based software system (CLIMEDO) to guide treatment intensification and improve adherence to ESC/EAS guideline-recommended LDL-cholesterol targets in patients following ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI).

Other names: Germany on Target protocolIntensive Lipid-Lowering Therapy

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)ACLY (ATP-citrate synthase)PCSK9 (Proprotein convertase subtilisin/kexin type 9)NPC1L1 (Niemann-pick C1-Like 1 transporter)

Beyond the preview

Go deeper on statins + ezetimibe + bempedoic acid + evolocumab + alirocumab + inclisiran.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on statins + ezetimibe + bempedoic acid + evolocumab + alirocumab + inclisiran.

Explore the full profile